Evogene Upsizes ATM to $3.3M, Reveals $1.75M Already Sold Amid Proxy Fight
EVGN sits 68% above its 52-week low of $0.37.
Summary
Evogene upsized its ATM offering to $3.3 million and revealed $1.75 million in shares already sold, adding dilution pressure amid an activist proxy battle and Nasdaq delisting risk.
Key Events · Financing and Capital Events · EVGN
-
ATM Upsized to $3.3M
The maximum aggregate offering price under the ATM program was increased from $2.93 million to $3.29 million, an upsize of $361,613.
-
$1.75M Already Sold
Evogene disclosed that $1,753,025.13 of ordinary shares have already been sold under the Sales Agreement to date, representing over half of the original $2.93 million capacity.
-
Dilution at Depressed Prices
With the stock trading at $0.58, the ATM sales are highly dilutive; the $1.75 million sold so far equates to roughly 3 million shares, or about 23% of the public float.
-
Proxy Fight Backdrop
The ATM upsize and sales come just days after an activist group acquired a 16.7% stake and demanded a special meeting to replace most of the board, adding governance uncertainty.
Analysis · EVGN · Industrial Applications And Services
Evogene increased its at-the-market offering capacity by $361,613 to $3.3 million and disclosed that $1.75 million in shares have already been sold under the program. The upsize and actual sales come as the company faces an activist proxy fight and delisting concerns, making the dilution more acute for existing shareholders. The ATM provides critical liquidity but at the cost of significant dilution at depressed prices.
At the time of this filing, EVGN was trading at $0.62 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $7.6M. The 52-week trading range was $0.37 to $1.50. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.